Executive Management
Ethan Shen, PhD
Chairman & CEO
Dr. Ethan Shen is an accomplished entrepreneur and academic leader committed to advancing global healthcare through scientific innovation and operational excellence. With more than two decades of experience across biotechnology, translational medicine, and leadership, Dr. Shen has built a distinguished reputation in the field.
“At YD Biopharma, we believe in the potential of science to shape a healthier future. Together, we aim to advance healthcare innovation and deliver meaningful solutions to those with the greatest needs.”
Benjamin Zhang, MD
Chief Medical Officer (CMO)
Dr. Benjamin Zhang is an accomplished leader in cancer immunotherapy and regenerative medicine, with extensive expertise in immune cell research, stem cell therapy, and clinical trial management. As Chief Medical Officer at YD Biopharma, Dr. Zhang leads initiatives in the development of gamma delta T cell expansion platforms and exosome-based therapies for oncology applications. He also serves as Chief Medical Officer at JY Biomedical, overseeing clinical operations and the advancement of investigational cancer therapies.
“At YD Biopharma, we are committed to translating scientific innovation into tangible patient benefits. Through a focus on collaboration and continuous advancement, we aim to contribute to the future of cancer care and regenerative medicine, bringing new possibilities to patients with unmet medical needs.”
Mr. Edmund Hen
Chief Financial Officer (CFO)
Mr. Edmund Hen is a seasoned financial executive with over two decades of experience in corporate finance, capital markets, and business strategy. As Chief Financial Officer (CFO) at YD Biopharma, he brings extensive expertise in financial management, regulatory compliance, and strategic business development. His leadership has been pivotal in supporting the company’s growth and expansion initiatives.
“At YD Biopharma, we recognize that sound financial stewardship is essential for driving sustainable growth. Through collaboration, innovation, and disciplined financial strategy, we are committed to advancing our mission and delivering long-term value to patients and stakeholders.”
Ms. May Tsai
Chief Operating Officer (COO)
May Tsai is a highly experienced executive with over two decades of expertise in supply chain management, procurement, project management, and risk management. As Chief Operating Officer (COO) at YD Biopharma, she brings extensive knowledge in driving business strategies, promoting operational excellence, and strengthening stakeholder engagement to support the company’s growth and global expansion initiatives.
“At YD Biopharma, we are committed to advancing the future of healthcare through innovation, operational efficiency, and strategic business development. Together, we aim to deliver impactful solutions that contribute to improving patient care and shaping the future of the industry.”
